Cover Image
市場調查報告書

癌症治療的奈米醫藥:市場及開發平台分析 (2015年)

Cancer Nanomedicine Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 324912
出版日期 內容資訊 英文 220 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療的奈米醫藥:市場及開發平台分析 (2015年) Cancer Nanomedicine Market & Pipeline Insight 2015
出版日期: 2015年02月25日 內容資訊: 英文 220 Pages
簡介

癌症治療的奈米粒子藥物輸送系統的開發,預計今後前景看好。尋找將藥物輸送到目的腫瘤部位比較安全的有效性高的奈米粒子材料是現在要求的課題,天然高分子蛋白質是構築奈米載體系統的確實材料。由於白蛋白奈米粒子的商業性成長,也吸引對其他的蛋白質的高度興趣。

本報告提供癌症治療的奈米醫藥的市場及開發平台趨勢的相關調查、奈米醫藥概要、癌症治療的需求與重要性、奈米醫藥的癌症治療的機制、技術發展的過程、開發平台的不同階段趨勢、已上市奈米醫藥概要、未來展望,以及彙整主要企業的簡介等。

第1章 簡介:奈米醫藥

第2章 癌症治療的奈米醫藥

第3章 癌症治療的奈米醫藥的必要性

第4章 癌症治療的奈米粒子藥物輸送系統的分類

第5章 奈米醫藥的癌症治療的機制

第6章 癌症治療的奈米醫藥:全球市場的展望

  • 目前市場方案
  • 癌症治療的奈米醫藥:臨床實驗平台概要

第7章 癌症治療的奈米醫藥:全球市場力學

  • 市場好意性的參數
  • 上市的課題

第8章 癌症治療的奈米醫藥:全球市場的未來展望

第9章 臨床實驗平台:各企業、適應症、階段

  • 研究
  • 前臨床
  • 第一階段
  • 第I/II階段
  • 第二階段
  • 第II/III階段
  • 第三階段

第10章 已上市奈米醫藥:各企業、適應症

第11章 開發延期、中止的開發平台

  • 沒有開發報告
  • 中止

第12章 競爭環境

  • Abraxis BioScience
  • Access Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Arrowhead Research
  • BIND Biosciences
  • Epeius Biotechnologies
  • Nanobiotix
  • NanoCarrier
  • 日本化藥
  • Samyang
  • 武田藥品工業

圖表一覽

目錄

During the last decade, there has been significant impact of the emergence of nanotechnology on clinical therapeutics. The pharmaceutical industry has witnessed advances in biocompatible nanoscale drug carriers in the form of liposomes and polymeric nanparticles which have the potential to deliver numerous drugs with more efficiency and safety. The advantages of nanoparticle drug delivery, specifically, at the systemic level, include longer circulation half-lives, improved pharmacokinetics and reduced side effects which are major reasons for its increasing popularity. In the field of cancer therapy, the nanoparticles could possibly depend heavily on the enhanced permeability and retention effect which is caused by leaky tumor vasculatures for better drug accumulation at the tumor sites. Owing to such benefits, the therapeutic nanoparticles as a form of drug delivery has become a very promising field and has the potential to successfully replace traditional chemotherapy.

Scientists and engineers have been specifically researching on discovering different approaches to deliver multiple therapeutic agents using a single drug nanocarrier. Given the fact that application of multiple drugs could possibly suppress the notorious phenomenon of cancer chemo-resistance, these efforts have been motivated to a great extent. It has been observed that the cancer cells tend to exhibit a diminishing response over the course of a chemo-treatment because they acquire defense mechanisms by over expressing drug efflux pumps, increasing drug metabolism, enhancing self-repairing ability or expressing altered drug targets. In order to reduce the cancer drug resistance for better therapeutic effectiveness, the “combination chemotherapy” has been adopted for a long time in the clinics as a primary cancer treatment regimen.

While on the one hand, applying multiple drugs with different molecular targets could possibly raise the genetic barriers needed to be overcome for cancer cell mutations, thereby delaying the cancer adaptation process. On the other hand, it has been proved that multiple drugs targeting the same cellular pathways could sometimes function synergistically for higher therapeutic efficacy and higher target selectivity. However, there are many shortcomings in the current combination chemotherapies. These include varying pharmacokinetics, biodistrubtions and membrane transport properties among different drug molecules which tend to make dosing and scheduling optimization extremely difficult. These challenges have made the researchers and clinicians to investigate more efficient approaches to incorporating nanotechnology with combination chemotherapy.

The future years are expected to be bright with regards to the development of nanoparticle drug delivery systems for cancer treatment. The identification of nanoparticle materials which are relatively safe and effective in delivering therapeutic agents to the target tumor sites is the need of the hour. The protein polymers from natural sources are considered to be promising materials for constructing the nanocarrier systems. With the commercial success of albumin-based nanoparticles, there has been significant amount of interest in other proteins also. By rationally designing protein nanoparticles based on their behaviors in the tumor microenvironment and based on cancer cell biology, improved efficacy and safety of cancer therapy can be achieved.

“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight:

  • Nanomedicine for Cancer Therapies
  • Cancer Nanoparticles Drug Delivery Systems Classification
  • Mechanism of Cancer Nanomedicine Therapy
  • Cancer Nanomedicine Clinical Pipeline Overview
  • Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
  • Cancer Nanomedicine Clinical Pipeline: 79 Drugs
  • Marketed Cancer Nanomedicine: 8 Drugs

Table of Contents

1. Introduction to Nanomedicine

2. Nanomedicine for Cancer Therapies

3. Need for Nanomedicine in Cancer Therapy

4. Cancer Nanoparticles Drug Delivery Systems Classification

5. Mechanism of Cancer Nanomedicine Therapy

6. Global Cancer Nanomedicine Market Outlook

  • 6.1. Current Market Scenario
  • 6.2. Cancer Nanomedicine Clinical Pipeline Overview

7. Global Cancer Nanomedicine Market Dynamics

  • 7.1. Favorable Market Parameters
  • 7.2. Commercialization Challenges

8. Global Cancer Nanomedicine Market Future Prospects

9. Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-II/III
  • 9.7. Phase-III

10. Marketed Cancer Nanomedicine by Company & Indication

11. Suspended & No Development Reported in Cancer Nanomedicine Clinical Pipeline

  • 11.1. No Development Reported
  • 11.2. Discontinued

12. Competitive Landscape

  • 12.1. Abraxis BioScience
  • 12.2. Access Pharmaceuticals
  • 12.3. Alnylam Pharmaceuticals
  • 12.4. Arrowhead Research
  • 12.5. BIND Biosciences
  • 12.6. Epeius Biotechnologies
  • 12.7. Nanobiotix
  • 12.8. NanoCarrier
  • 12.9. Nippon Kayaku
  • 12.10. Samyang
  • 12.11. Takeda Pharmaceutical

List of Figures

  • Figure 1-1: Introduction to Nanomedicine
  • Figure 1-2: Applications Areas of Nanomedicine
  • Figure 2-1: Technology Evolution of Targeted Drug Delivery using Nanoparticles for Cancer Treatment
  • Figure 3-1: Need & Importance of Nano Drug Delivery for Cancer
  • Figure 4-1: Types of Nanoparticles Drug Delivery Systems
  • Figure 5-1: Mechanism of Cancer Nanomedicine Therapy
  • Figure 5-2: Multiblock Polymer Nanoparticles Attacks Tumors- Step by Step Process of Drug Delivery
  • Figure 6-1: Novel Drug Delivery Systems for Cancer
  • Figure 6-2: Cancer Nanomedicine Pipeline by Phase (%), 2015
  • Figure 6-3: Cancer Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 6-4: No Development Reported in Cancer Nanomedicine Pipeline by Phase (%), 2015
  • Figure 6-5: No Development Reported in Cancer Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 6-6: Discontinued Cancer Nanomedicine Pipeline by Phase (%), 2015
  • Figure 6-7: Discontinued Cancer Nanomedicine Clinical Pipeline by Phase (Number), 2015
  • Figure 12-1: Arrowhead Research Corporation Clinical Pipeline
  • Figure 12-2: NanoCarrier Clinical Pipeline

List of Tables

  • Table 4 1: Liposomes for Combination Cancer Therapy
  • Table 4 2: Polymeric nanoparticles & Polymer Drug Conjugates for Combination Cancer Therapy
  • Table 4 3: Dendrimers & other Nanoparticles for Combination Cancer Therapy
Back to Top